<DOC>
	<DOCNO>NCT02929719</DOCNO>
	<brief_summary>Therapeutic equivalence safety study</brief_summary>
	<brief_title>Study Comparing Test Aczone 5 % Both Placebo Control Treatment Acne Vulgaris</brief_title>
	<detailed_description>To evaluate therapeutic equivalence safety Test formulation market Reference Listed Drug ( RLD ) . To demonstrate superiority efficacy Test Reference product placebo control treatment . To compare safety Test , Reference Placebo treatment .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<criteria>Healthy male non pregnant female age ≥ 12 ≤ 40years clinical diagnosis acne vulgaris Subjects must definite clinical diagnosis acne vulgaris severity grade 2 , 3 , 4 per Investigator 's Global Assessment ( IGA ) ( per Table 1 ) Female Subjects pregnant , nurse plan become pregnant study participation .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>